Westlake Therapeutics Announces Completion of New Funding Round Exceeding RMB 100 MillionRecently, Westlake Therapeutics (hereinafter referred to as "Westlake Bio") announced the completion of a new round of financing exceeding RMB 100 million. This round was co-led by Beijing Shijingshan District Modern Innovation Industry Development Fund Co., Ltd. (hereinafter referred to as "Shijingshan Modern Innovation Industry Fund") and Ruili Synthetic Biology Fund, with participation from prominent industry investors in follow-on investments. Existing shareholders, including Yifeng Capital, Huafang Capital, and Sequoia China, continued to increase their investments.

The proceeds from this round of financing will be primarily used to advance the development of the Company’s red blood cell-based drug pipeline in therapeutic areas such as oncology and autoimmune diseases, accelerate clinical validation and regulatory filings for core products, and further strengthen capabilities in research and development, manufacturing, and industrialization.

Yifeng Capital participated in Westlake Therapeutics’ financing rounds in both 2022 and 2025, establishing itself as a core long-term shareholder accompanying the company’s growth. Looking ahead, Yifeng Capital will continue to deepen its strategic synergy with Westlake Therapeutics. Beyond providing capital support, it will fully leverage its industrial resources and ecosystem network advantages in the healthcare sector to help the company accelerate breakthroughs in the fields of tumor immunology and autoimmune diseases.

END